Promega, J1342, Glucose Uptake-Glo™ Assay

Measure Metabolic Changes in Cancer and Adipocyte Cell Lines
MCF7 Cancer Cells
In the cancer model, when cells are oxygen-starved, the hypoxic conditions shift cellular metabolism from oxidative phosphorylation to glycolysis. This results in increased glucose uptake.
MCF7 cells grown under hypoxia (1% oxygen) show an increase in Glucose Uptake-Glo™, indicating an increased glycolytic rate. The same cells demonstrate no significant change in viability using the RealTime-Glo™ and CellTiter-Fluor™ Assays.
Adipocyte Cells
Using the adipocyte model, we demonstrate that changes in glucose uptake for 3T3L1-MBX adipocytes did not have significant effects on cell health. Multiplexing the RealTime-Glo™ Assay with the Glucose Uptake-Glo™ Assay separates immediate effects on glucose uptake from global effects on cell health.
Results of the Glucose Uptake-Glo™ Assay when adipocyte cells are treated under various conditions, where "None" indicates the basal level of glucose uptake. Insulin induces translocation of glucose transporters to the cell surface, and thus increases glucose uptake above basal levels. Cytochalasin B is a glucose transporter inhibitor which decreases glucose uptake. LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, is an essential insulin signaling enzyme which decreases glucose uptake relative to insulin alone.
Results of the RealTime-Glo™ Assay when adipocyte cells are treated under various conditions, where "None" indicates the basal level of glucose uptake. Although there are dramatic changes in glucose uptake, as seen in the accompanying panel, there are minimal changes in viability as measured by the RealTime-Glo™ Assay.